Jaume Capdevila

8PUBLICATIONS
49CO-AUTHORS
Molecular targetsRadiation therapyCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersNeurology and neuromuscular diseases
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Feb 20, 2026
Axitinib and Long-Acting Octreotide in Advanced Extrapancreatic Neuroendocrine Tumors: A Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Trial (AXINET, GETNE 1107).

Rocio Garcia-Carbonero, Marta Benavent, Paula Jimenez-Fonseca

|Apr 11, 2025
Spanish consensus on the diagnosis and management of adrenocortical carcinoma.

Marta Araujo-Castro, Cristina Álvarez-Escola, Ana Casteràs

|Jan 20, 2023
Locoregional Failure During and After Short-course Radiotherapy Followed by Chemotherapy and Surgery Compared With Long-course Chemoradiotherapy and Surgery: A 5-Year Follow-up of the RAPIDO Trial.

Esmée A Dijkstra, Per J Nilsson, Geke A P Hospers

|Jun 23, 2022
Clinical activity of CC-90011, an oral, potent, and reversible LSD1 inhibitor, in advanced malignancies.

Antoine Hollebecque, Stefania Salvagni, Ruth Plummer

|May 04, 2021
Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509).

Jaume Capdevila, Nicola Fazio, Carlos Lopez

|Dec 19, 2019
VITAL phase 2 study: Upfront 5-fluorouracil, mitomycin-C, panitumumab and radiotherapy treatment in nonmetastatic squamous cell carcinomas of the anal canal (GEMCAD 09-02).

Jaime Feliu, Rocio Garcia-Carbonero, Jaume Capdevila

Pageof 2

Frequent Collaborators

2 joint publications

Ana Custodio

2 joint publications

Paula Jimenez-Fonseca

2 joint publications

Adelaida La Casta

2 joint publications

Toni Ibrahim